SELECTIVE INHIBITION OF KRAS SIGNALING BY COMBINATION OF LOW DOSE RAPAMYCIN AND PACLITAXEL IN VIVO
Background. Therapy with compounds potentially capable to block KRAS oncogene signaling pathway is perspective direction in modern oncopharmacology. The aim of current study was to investigate effects of the combined treatment with rapamycin (RAP) and paclitaxel (PAC) in transgenic zebrafish (Danio...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2018-07-01
|
Series: | Успехи молекулярной онкологии |
Subjects: | |
Online Access: | https://umo.abvpress.ru/jour/article/view/146 |